Navigation Links
Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer

NEW YORK, April 10, 2007 /PRNewswire-FirstCall/ -- ImClone Systems Incorporated and Bristol-Myers Squibb Company today announced that a Phase III study of ERBITUX(R) (Cetuximab) plus gemcitabine (a chemotherapy) in patients with locally advanced unresectable or metastatic pancreatic cancer did not meet its primary endpoint of improving overall survival.

Conducted by the Southwest Oncology Group (SWOG), a cancer center network sponsored by the National Cancer Institute, the open-label, randomized study compared ERBITUX plus gemcitabine to gemcitabine alone in more than 700 patients with pancreatic cancer in the first-line treatment setting. The study was conducted in centers throughout the United States and Canada. It was completed in a significantly shorter time than projected, providing a timely answer to an important research question. SWOG has informed ImClone and Bristol-Myers Squibb that the primary study endpoint of statistically improving overall survival was not met. The three parties -- SWOG, ImClone, and Bristol-Myers Squibb -- will engage in joint efforts to fully interpret these results.

"This study was designed to examine the Phase II results we previously observed for ERBITUX in patients with pancreatic cancer," stated Eric K. Rowinsky, M.D., Chief Medical Officer and Senior Vice President of ImClone Systems. "We still consider pancreatic cancer to be of the utmost priority and we intend to pursue additional evaluations with ERBITUX including a pilot study of ERBITUX and bevacizumab with or without gemcitabine, as well as our pipeline agents, to improve the outcome for patients with pancreatic cancer."

"Pancreatic cancer is a devastating disease with few effective treatment options, and it is unfortunate that the use of ERBITUX in this trial has not demonstrated the benefit it has shown in other tumors," said Martin Birkhofer, M.D., Vice President, Oncology Global Medical Affa
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Positive Results Prompt US National Cancer Institute to Make Glivec Available to Patients in Post-Surgical GIST Study
3. Positive Results Prompt US National Cancer Institute to Make Gleevec Available To Patients in Post-Surgical Gist Study
4. Survival Data Available From Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
5. Survival Data Available from Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
6. Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting
7. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
8. Randomized Phase III Trial Showed Erbitux Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis

Post Your Comments:
(Date:12/1/2009)...na, Dec. 1 /PRNewswire-Asia-FirstCall/ -- Tianyin,...nufacturer and supplier of,modernized traditional ...today,announced that it has received approvals fro...SFDA) to produce Pediatric Fever and Cough Oral Li...umber Z20093060) and Antibacterial,and Anti-inflam...
(Date:12/1/2009)...ec. 1 Tibotec Therapeutics, a divi...ounced today that it is launching a new initiative...people of color living with HIV/AIDS. Through a co...vents, media outreach and a new Web site, www.The...from the GRACE study, the largest clinical trial i...
(Date:12/1/2009)...f., Dec. 1 Codexis, Inc. today ann...gning of its second agreement this year with Teva ...t generic drug manufacturer. The new agreement co...odexis announced an earlier agreement with Teva on...ll use Codexis biocatalysis technology for key pro...
Breaking Medicine Technology:Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products 2Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products 3Tibotec Therapeutics Launches GRACE Campaign for Women and People of Color Living With HIV/AIDS 2Tibotec Therapeutics Launches GRACE Campaign for Women and People of Color Living With HIV/AIDS 3Tibotec Therapeutics Launches GRACE Campaign for Women and People of Color Living With HIV/AIDS 4Tibotec Therapeutics Launches GRACE Campaign for Women and People of Color Living With HIV/AIDS 5Tibotec Therapeutics Launches GRACE Campaign for Women and People of Color Living With HIV/AIDS 6Tibotec Therapeutics Launches GRACE Campaign for Women and People of Color Living With HIV/AIDS 7Codexis Expands Collaboration with Teva 2Riviera Laser Studios Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 54349 1Riviera Laser Studios Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 54349 2Riviera Laser Studios Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 54349 3Psoriasis Video Contest Launched to Encourage Psoriasis Patients to Connect and Collaborate 54344 1Psoriasis Video Contest Launched to Encourage Psoriasis Patients to Connect and Collaborate 54344 2CRF announces late breaking trials to be presented at TCT 2009 in San Francisco 54339 1CRF announces late breaking trials to be presented at TCT 2009 in San Francisco 54339 2CRF announces late breaking trials to be presented at TCT 2009 in San Francisco 54339 3
...o., March 13 Synbiotics Corporation today,announc...e Food & Drug,Administration (FDA) for the use of ...strip in humans. This represents Synbiotics first ...etplace. While it is not Synbiotics,initial intent... it is,actively seeking an established strategic h...
...March 12 Eli Lilly and Company,(NYSE: LLY ), str...ny,practices as alleged by the Connecticut Attorne...ued March 11, 2008., The tone and content of the ...tly be taking Zyprexa to treat a life-threatening ...no acknowledgement of the,seriousness of schizophr...
Other Medicine Technology:Synbiotics Corporation Announces Human Submission for FluDetect(R) 2Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release 2Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release 3Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release 4
(Date:12/1/2009)... Study suggests that ,less affirming, isolating b...TUESDAY, Dec. 1 (HealthDay News) -- A new study su..." and influence others to feel lonely, too. , "...son -- up to three degrees of separation," said Ja... the December issue of the Journal of Personality...
(Date:12/1/2009)..., PHILADELPHIA (December 1, 2009) Wistar Instit...ity of Pennsylvania and New York University have i... indicate early-stage lung tumors in people at hig...ublished online December 1 in Cancer Research , a...search, could lead to a simple blood test to detec...
(Date:12/1/2009)..., Practitioners of any me...ranscription are breathing a sigh of relief this w... iPhone. The application, released over the holid...transcribe voice recordings to do so quickly and s... (PRWEB) December 1, 2009 -- Th...
(Date:12/1/2009)..., , RESEARCH TRIANGLE PARK, N.C., Dec....re initiated in 2001 and have expanded over the ye...globally. The facility which was originally set up...e. Pharmacy services, as part of the suite of serv...harma industry as a valuable offering. ,, The p...
(Date:12/1/2009)..., , LEHIGH VALLEY, Pa., Dec. 1 /PRNewswir...said it has completed the previously announced sal...usiness, marketed under the Airthane® and Ver... owned subsidiary of global polyurethane chemicals...s Air Products, manufacturing facility in Paulsbor...
Breaking Medicine News(10 mins):Health News:Loneliness May Be Catching 2Health News:Loneliness May Be Catching 3Health News:Wistar-led research team discovers genetic pattern that indicates early-stage lung cancer 2Health News:Wistar-led research team discovers genetic pattern that indicates early-stage lung cancer 3Health News:Medical and Legal Professionals Find Relief Leveraging Apple iPhone App for Dictation and Transcription 'On the Go' 2Health News:Air Products Completes Sale of Polyurethane Pre-Polymers Business to COIM USA 2
...ance to Acquire Lilly,s Greenfield, Indiana Campus...ear, $1.6 Billion Services Contract, PRINCETON, N...rovider of drug development services, announced to...ill acquire,Lilly,s 450-acre early drug developmen...
...IEGO, Aug. 6 Pacira Pharmaceuticals, Inc., an,acu...nounced the addition,of a key senior executive to ...joins Pacira as the Chief Financial Officer. Mr. S...ently he has,been consulting to Genzyme Corporatio...
...N, Aug. 6 Half of UK physicians believe that the,...ill belittle their,professionalism, and 65% fear i...are research. In its study of more than 200 GPs ac...two-thirds anticipating that it will be no more th...
...A, N.H., Aug. 6 iCAD, Inc. (Nasdaq:,ICAD), an ind... (CAD),solutions for the early identification of c...nd Chief Executive Officer and Darlene Deptula-Hic...Tuesday, August 12, 2008 at 9:30 a.m. (Eastern Day...
...w York, August 6, 2008 Although maternal suicide ..., suicide attempts often have long-lasting effects...d in the August 2008 issue of the American Journa...s a strong predictor of post-partum suicide attemp...
...semont, Ill. August 5, 2008 Times are tough for ...eed to work hard by providing plenty of nutrition.... economic and nutritional value because they pack ...that addresses childhood obesity, stresses the imp...
Other Medicine News:Health News:Covance and Lilly Enter Into a Strategic R&D Collaboration 2Health News:Covance and Lilly Enter Into a Strategic R&D Collaboration 3Health News:Covance and Lilly Enter Into a Strategic R&D Collaboration 4Health News:Pacira Pharmaceuticals, Inc. Adds Experienced CFO James S. Scibetta to Leadership of the Organization 2Health News:UK Physicians Fear New Revalidation Procedures Will Reduce Morale, Decrease Time with Patients and Belittle GP Professionalism, According to New TNS Healthcare Research 2Health News:UK Physicians Fear New Revalidation Procedures Will Reduce Morale, Decrease Time with Patients and Belittle GP Professionalism, According to New TNS Healthcare Research 3Health News:UK Physicians Fear New Revalidation Procedures Will Reduce Morale, Decrease Time with Patients and Belittle GP Professionalism, According to New TNS Healthcare Research 4Health News:iCAD to Present at Canaccord Adams 28th Annual Global Growth Conference 2Health News:Post-partum suicide attempt risks studied 2Health News:Invest in your family's health by budgeting for nutrient-rich foods 2Health News:Invest in your family's health by budgeting for nutrient-rich foods 3
Immersion Oil, 1,250 cs
Immersion oil for microscopy
...guChek XS system is a compact, convenient and prec... experience a significant improvement in life qual...t of their condition. , , The CoaguChek XS sys...k S system. It encompasses several innovative tech...
First Check 12 Drug Test
Medicine Products: